CD274 Rabbit Polyclonal Antibody
To Order Contact Us Below:
CD274 Polyclonal Antibody |
ES8791-100ul |
ELK Biotech |
100ul |
EUR 334.8 |
Description: A Rabbit Polyclonal antibody against CD274 from Human. This antibody is tested and validated for IHC, WB, ELISA |
CD274 Polyclonal Antibody |
ES8791-50ul |
ELK Biotech |
50ul |
EUR 248.4 |
Description: A Rabbit Polyclonal antibody against CD274 from Human. This antibody is tested and validated for IHC, WB, ELISA |
CD274 Antibody |
1-CSB-PA004911GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD274. Recognizes CD274 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
CD274 Antibody |
1-CSB-PA878942ESR1HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD274. Recognizes CD274 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
CD274 Antibody |
32363-100ul |
SAB |
100ul |
EUR 302.4 |
CD274 Antibody |
43858-100ul |
SAB |
100ul |
EUR 302.4 |
CD274 antibody |
70R-16265 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal CD274 antibody |
Polyclonal CD274 Antibody (C-term) |
APR03998G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD274 (C-term). This antibody is tested and proven to work in the following applications: |
Anti-PD-L1 (CD274) Rabbit Monoclonal Antibody |
M00109 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal PD-L1 (CD274) Antibody. Validated in IHC-P, WB and tested in Human, Mouse, Rat. |
Polyclonal CD274 Antibody - C-terminal region |
APR01550G |
Leading Biology |
0.05mg |
EUR 633.6 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human CD274 - C-terminal region. This antibody is tested and proven to work in the following applications: |
CD274(PD1L1) Antibody |
48238-100ul |
SAB |
100ul |
EUR 399.6 |
CD274(PD1L1) Antibody |
48238-50ul |
SAB |
50ul |
EUR 286.8 |
CD274 Antibody (FITC) |
abx140489-100tests |
Abbexa |
100 tests |
EUR 510 |
|
Anti-CD274 antibody |
STJ113753 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. |
Anti-CD274 antibody |
STJ160016 |
St John's Laboratory |
1 mL C |
EUR 652.8 |
Description: Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma. |
Anti-CD274 antibody |
STJ22985 |
St John's Laboratory |
100 µl |
EUR 332.4 |
Description: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. |
Anti-CD274 antibody |
STJ98996 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Rabbit polyclonal to CD274. |
Rabbit Anti-CD274 monoclonal antibody, clone KK19-06 |
CAB-722RH |
Creative Diagnostics |
100 ul |
EUR 932.4 |
anti-CD274 |
YF-PA26076 |
Abfrontier |
50 ul |
EUR 400.8 |
Description: Mouse polyclonal to CD274 |
Polyclonal Goat Anti-CD274 / PD-L1 Antibody |
APG00067G |
Leading Biology |
0.1mg |
EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CD274 / PD-L1 . This antibody is tested and proven to work in the following applications: |
Polyclonal B7-H1 / PD-L1 / CD274 Antibody |
APR03374G |
Leading Biology |
0.05ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human B7-H1 / PD-L1 / CD274 . This antibody is tested and proven to work in the following applications: |
CD274(PD1L1) Conjugated Antibody |
C48238 |
SAB |
100ul |
EUR 476.4 |
Anti-PD-L1 (CD274) (B7-H1), Rabbit Monoclonal Antibody |
A1824-50 |
Biovision |
each |
Ask for price |
Goat Anti Human Cd274 (C-Terminal) Polyclonal Antibody |
CPBT-65080GH |
Creative Diagnostics |
0.1 mg |
EUR 1008 |
CD274 cloning plasmid |
CSB-CL878942HU-10ug |
Cusabio |
10ug |
EUR 279.6 |
|
Description: A cloning plasmid for the CD274 gene. |
CD274 Blocking Peptide |
DF6526-BP |
Affbiotech |
1mg |
EUR 234 |
PD-L1, CD274 |
E6TA00108 |
EnoGene |
0.1mg |
EUR 411.6 |
CD274, mouse recombinant |
7311-100 |
Biovision |
each |
EUR 444 |
PD-L1 (CD274) |
100443-1 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
PD-L1 (CD274) |
100443-2 |
BPS Bioscience |
1 mg |
EUR 2720 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
anti- PD-L1/CD274 antibody |
FNab06280 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against PD-L1/CD274 |
anti- PD-L1/CD274 antibody |
FNab06281 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against PD-L1/CD274 |
Anti-PD-L1/CD274 Antibody |
PA1851 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1/CD274 Antibody |
PB9154 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1/CD274 Antibody |
PB9994 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 |
M00109-1 |
BosterBio |
100uL |
EUR 512.4 |
Description: Anti-PD-L1 (CD274) (B7-H1) Rabbit Monoclonal Antibody, Clone#RM320 tested in WB, IHC, reactive to Human |
PD-L1 Antibody / B7-H1 / CD274 |
V7822-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7822-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7822SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955BTN |
NSJ Bioreagents |
500 ul |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955PE-100T |
NSJ Bioreagents |
100 Tests |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155-20UG |
NSJ Bioreagents |
20ug |
EUR 219 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 499 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
Anti-PD-L1 (CD274) Neutralizing Antibody |
71213 |
BPS Bioscience |
100 µg |
EUR 505 |
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested. |
Human CD274 shRNA Plasmid |
20-abx959214 |
Abbexa |
|
|
|
Mouse CD274 shRNA Plasmid |
20-abx975220 |
Abbexa |
|
|
|
PD-L1 (CD274) siRNA |
20-abx910978 |
Abbexa |
|
|
|
PD-L1 (CD274) siRNA |
20-abx910979 |
Abbexa |
|
|
|
Anti-Hu CD274 PE |
1P-177-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD274 PE |
1P-177-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD274 APC |
1A-177-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD274 FITC |
1F-177-T100 |
ExBio |
100 tests |
EUR 244.8 |
Anti-Hu CD274 Purified |
11-177-C025 |
ExBio |
0.025 mg |
EUR 118.8 |
Anti-Hu CD274 Purified |
11-177-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
CD274 protein (His tag) |
80R-2283 |
Fitzgerald |
20 ug |
EUR 386.4 |
Description: Purified recombinant Human CD274 Protein (His tag) |
CD274 protein (His tag) |
80R-2388 |
Fitzgerald |
100 ug |
EUR 386.4 |
Description: Purified recombinant Mouse CD274 protein (His tag) |
CD274 Mouse Recombinant Protein |
PROTQ9EP73 |
BosterBio |
Regular: 20ug |
EUR 380.4 |
Description: CD274 Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 246 amino acids (19-239 a.a) and having a molecular mass of 27.6kDa (Molecular size on SDS-PAGE will appear higher).;CD274 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
CD274 Human Recombinant Protein |
PROTQ9NZQ7 |
BosterBio |
Regular: 10ug |
EUR 380.4 |
Description: CD274 Human Recombinant produced in E. coli is a single polypeptide chain containing 245 amino acids (19-238) and having a molecular mass of 27.9kDa (Molecular weight on SDS-PAGE will appear higher).;CD274 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
CD274 Recombinant Protein (Human) |
RP037906 |
ABM |
100 ug |
Ask for price |
CD274 Recombinant Protein (Mouse) |
RP122489 |
ABM |
100 ug |
Ask for price |
CD274 Recombinant Protein (Rat) |
RP193907 |
ABM |
100 ug |
Ask for price |
Anti-PD-L1/B7-H1/CD274 Antibody |
A00109 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-Hu CD274 Alexa Fluor700 |
A7-177-T100 |
ExBio |
100 tests |
EUR 322.8 |
CD274 ELISA Kit (Human) (OKBB00999) |
OKBB00999 |
Aviva Systems Biology |
96 Wells |
EUR 606 |
Description: Description of target: Programmed death-ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a protein that in humans is encoded by the CD274 gene. PD-L1 is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Normally the immune system reacts to foreign antigens where there is some accumulation in the lymph nodes or spleen which triggers a proliferation of antigen-specific CD8+ T cell. The formation of PD-1 receptor / PD-L1 or B7.1 receptor /PD-L1 ligand complex transmits an inhibitory signal which reduces the proliferation of these CD8+ T cells at the lymph nodes and supplementary to that PD-1 is also able to control the accumulation of foreign antigen specific T cells in the lymph nodes through apoptosis which is further mediated by a lower regulation of the gene Bcl-2.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: <12pg/ml |
CD274 ELISA Kit (Mouse) (OKBB01000) |
OKBB01000 |
Aviva Systems Biology |
96 Wells |
EUR 606 |
Description: Description of target: Programmed death-ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1), is a protein that in humans is encoded by the CD274 gene. PD-L1 is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Normally the immune system reacts to foreign antigens where there is some accumulation in the lymph nodes or spleen which triggers a proliferation of antigen-specific CD8+ T cell. The formation of PD-1 receptor / PD-L1 or B7.1 receptor /PD-L1 ligand complex transmits an inhibitory signal which reduces the proliferation of these CD8+ T cells at the lymph nodes and supplementary to that PD-1 is also able to control the accumulation of foreign antigen specific T cells in the lymph nodes through apoptosis which is further mediated by a lower regulation of the gene Bcl-2.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml |
CD274 ELISA Kit (Mouse) (OKAN05739) |
OKAN05739 |
Aviva Systems Biology |
96 Wells |
EUR 950.4 |
Description: Description of target: The protein encoded by this gene is an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Mice deficient for this gene display a variety of phenotypes including decreased allogeneic fetal survival rates and severe experimental autoimmune encephalomyelitis.;Species reactivity: Mouse;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.055 ng/mL |
CD274 ELISA Kit (Human) (OKAN05757) |
OKAN05757 |
Aviva Systems Biology |
96 Wells |
EUR 950.4 |
Description: Description of target: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.056 ng/mL |
CD274 ELISA Kit (Human) (OKAN05758) |
OKAN05758 |
Aviva Systems Biology |
96 Wells |
EUR 950.4 |
Description: Description of target: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.118 ng/mL |
CD274 ELISA Kit (Human) (OKCD06821) |
OKCD06821 |
Aviva Systems Biology |
96 Wells |
EUR 903.6 |
Description: Description of target: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.056ng/mL |
CD274 ELISA Kit (Mouse) (OKCD06822) |
OKCD06822 |
Aviva Systems Biology |
96 Wells |
EUR 934.8 |
Description: Description of target: The protein encoded by this gene is an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Mice deficient for this gene display a variety of phenotypes including decreased allogeneic fetal survival rates and severe experimental autoimmune encephalomyelitis.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: < 0.055ng/mL |
Cd274 ORF Vector (Rat) (pORF) |
ORF064637 |
ABM |
1.0 ug DNA |
EUR 607.2 |
CD274 ELISA Kit (Rat) (OKEI00914) |
OKEI00914 |
Aviva Systems Biology |
96 Wells |
EUR 920.4 |
Description: Description of target: ;Species reactivity: Rat;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 46.9 pg/mL |
CD274 ORF Vector (Human) (pORF) |
ORF012636 |
ABM |
1.0 ug DNA |
EUR 114 |
CD274 ELISA Kit (Human) (OKCD09541) |
OKCD09541 |
Aviva Systems Biology |
96 Wells |
EUR 872.4 |
Description: Description of target: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.112ng/mL |
Cd274 ORF Vector (Mouse) (pORF) |
ORF040831 |
ABM |
1.0 ug DNA |
EUR 114 |
PD-L1/B7-H1/CD274 |
E21-J88 |
EnoGene |
10ug |
EUR 411.6 |
Anti-Hu CD274 PE-Cy7 |
T7-177-T100 |
ExBio |
100 tests |
EUR 321.6 |
Anti-Hu CD274 PerCP-Cy5.5 |
T9-177-T100 |
ExBio |
100 tests |
EUR 422.4 |
PD-L1 /CD274, Human Recombinant |
P1023-10 |
Biovision |
each |
EUR 301.2 |
PD-L1 /CD274, Human Recombinant |
P1023-50 |
Biovision |
each |
EUR 823.2 |
Rat Anti Mouse Cd274 Monoclonal Antibody,LOW ENDOTOXIN |
CABT-47439RM |
Creative Diagnostics |
0.5 mg |
EUR 1057.2 |
Mouse Anti-Human CD274 (PD-L1) mAbConjugated Antibody |
CCM025 |
SAB |
100ul |
EUR 476.4 |
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx140406-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx224294-100ug |
Abbexa |
100 ug |
EUR 493.2 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx414406-025mg |
Abbexa |
0.25 mg |
EUR 678 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx414407-05mg |
Abbexa |
0.5 mg |
EUR 994.8 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx414408-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx414409-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx414411-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx412030-01mg |
Abbexa |
0.1 mg |
EUR 644.4 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody |
abx412147-01mg |
Abbexa |
0.1 mg |
EUR 844.8 |
|
Anti-Hu CD274 Purified Low Endotoxin |
12-177-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
CD274 sgRNA CRISPR Lentivector set (Human) |
K0407201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Cd274 sgRNA CRISPR Lentivector set (Rat) |
K6192401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Cd274 sgRNA CRISPR Lentivector set (Mouse) |
K4385401 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
Human, CD274 Human Recombinant Protein, Sf9 |
PROTQ9EP73-1 |
BosterBio |
Regular: 10ug |
EUR 380.4 |
Description: CD274 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 462 amino acids (19-238a.a.) and having a molecular mass of 52.5kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa). CD274 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques. |
Recombinant CD274 Protein (Met1-Arg238) [His] |
VAng-Cr3786-100g |
Creative Biolabs |
100 µg |
EUR 880.8 |
Description: Recombinant CD274 Protein (Met1-Arg238) fused with a His tag at C-terminus was expressed in Mammalian cells, with a molecular weight of 35 kDa. (Uniprot ID: Q9NZQ7) |
PD-L1/CD274 (Human) ELISA Kit |
K4155-100 |
Biovision |
each |
EUR 966 |
Mouse PD-L1 (CD274), Fc fusion |
71117-1 |
BPS Bioscience |
50 µg |
EUR 215 |
Description: Mouse secreted Programmed Cell Death 1_x000D_Ligand 1 (PD-L1)-Fc fusion protein, also_x000D_known as CD274 and B7 homolog 1 (B7-_x000D_H1), GenBank Accession No. NM_021893,_x000D_a.a. 19-238, fused at the C-terminus to the_x000D_Fc portion of mouse IgG2a, expressed in a_x000D_HEK293 cell expression system. MW = 51.8_x000D_kDa. |
Mouse PD-L1 (CD274), Fc fusion |
71117-2 |
BPS Bioscience |
100 µg |
EUR 325 |
Description: Mouse secreted Programmed Cell Death 1_x000D_Ligand 1 (PD-L1)-Fc fusion protein, also_x000D_known as CD274 and B7 homolog 1 (B7-_x000D_H1), GenBank Accession No. NM_021893,_x000D_a.a. 19-238, fused at the C-terminus to the_x000D_Fc portion of mouse IgG2a, expressed in a_x000D_HEK293 cell expression system. MW = 51.8_x000D_kDa. |
Programmed Cell Death 1 Ligand 1 (CD274) Antibody (PE) |
abx140427-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
Programmed Cell Death 1 Ligand 1 (CD274) Antibody (APC) |
abx140453-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
CD274 Rabbit Polyclonal Antibody